市場調查報告書

黏多醣症(MPS)治療的市場規模:各治療、MPS類型(MPS-I、MPS-II、MPS-IV、MPS-VI、MPS-VII、其他)、終端用戶、地區 - 佔有率,展望,機會分析(2020年∼ 2027年)

Mucopolysaccharidosis Treatment Market, By Treatment, By MPS Type (MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, and Others ), By End User, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 968722
出版日期 內容資訊 英文 198 Pages
商品交期: 2-3個工作天內
價格
黏多醣症(MPS)治療的市場規模:各治療、MPS類型(MPS-I、MPS-II、MPS-IV、MPS-VI、MPS-VII、其他)、終端用戶、地區 - 佔有率,展望,機會分析(2020年∼ 2027年) Mucopolysaccharidosis Treatment Market, By Treatment, By MPS Type (MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, and Others ), By End User, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年09月18日內容資訊: 英文 198 Pages
簡介

黏多醣症(MPS)障礙相關的神經學症狀,引起重度的障礙。現在使用的治療方法因為不能治療神經學症狀,許多患者需要恰當的治療,推動對黏多醣症(MPS)的全部類型的症狀的有效治療方法的需求,預計促進在預測期間內的黏多醣症(MPS)治療市場成長。

還有為黏多醣症(MPS)患者開發免費測試計劃市場參與者的協作和聯盟等對成長策略的關注預期支持市場成長。

本報告提供全球黏多醣症(MPS)治療市場的相關調查,市場趨勢和機會,法規,成長及阻礙因素,各治療、MPS類型、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 調查目的、前提條件

第2章 市場展望

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
    • 市場明細:各治療
    • 市場明細:各MPS類型
    • 市場明細:各終端用戶
    • 市場明細:各地區
  • Coherent Opportunity Map (COM)

第3章 市場動態,法規,及趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 主要的發展
  • PEST分析

第4章 Covid-19大流行的影響

  • COVID-19大流行中的市場分析
  • COVID-19大流行後的市場分析
  • 主要的發展

第5章 市場分析:各治療(2016-2027)

  • 簡介
  • 酵素補充療法
  • 幹細胞治療

第6章 市場分析:各MPS類型(2016-2027)

  • 簡介
  • MPS-I
  • MPS-II
  • MPS-IV
  • MPS-VI
  • MPS-VII
  • 其他(MPS-III及MPS-IX)

第7章 市場分析:各終端用戶(2016-2027)

  • 簡介
  • 醫院
  • 專門診所
  • 其他

第8章 市場分析:各地區(2016-2027)

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第9章 競爭情形

  • 熱圖分析
  • 市場佔有率分析
    • Takeda Pharmaceutical Company Limited
    • BioMarin Pharmaceuticals, Inc.
    • Ultragenyx Pharmaceutical Inc.
    • Sarepta Therapeutics
    • Abeona Therapeutics Inc.
    • Eloxx Pharmaceuticals
    • Esteve
    • Immusoft Corporation
    • Inventiva
    • GC Pharma
    • JCR Pharmaceuticals Co Ltd.
    • RegenxBio Inc.
    • Sangamo Therapeutics, Inc.
    • Bioasis Technologies Inc.
    • Paradigm Biopharmaceuticals Ltd.
  • 分析師的見解

第10章 Section

目錄

Title:
Mucopolysaccharidosis (MPS) Treatment Market, By Treatment (Enzyme Replacement Therapy and Stem Cell Therapy ), By MPS Type (MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, and Others (MPS-III and MPS-IX)), By End User (Hospitals, Specialty Clinics, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Currently available therapeutics such as Elaprase and Aldurazyme are not able to appropriately address the neurological symptoms and complications of patients suffering from mucopolysaccharidosis (MPS), as these drugs are not capable of crossing blood brain barrier, a key requirement for effective management of mucopolysaccharidosis (MPS) disorder.

The neurological symptoms associated with mucopolysaccharidosis (MPS) disorder are severely disabling. The therapeutics used currently are not able to treat the neurological symptoms, thus a significant proportion of the population is in need of appropriate treatment. This is expected to propel demand for effective therapeutics, which aid in the management of all types of symptoms of mucopolysaccharidosis (MPS). This is expected to drive growth of the MPS treatment market during the forecast period.

Market Dynamics

Market players are focusing on various inorganic growth strategies such as collaborations and partnerships in order to develop no cost testing programs for patients with mucopolysaccharidosis (MPS), which is expected to boost growth of the global mucopolysaccharidosis (MPS) treatment market. For instance, in October 2018, Sanofi Genzyme and PerkinElmer, Inc. collaborated in order to develop a 'Lantern Project', to provide a no-cost testing program for patients in the U.S. and who suffer from specific types of lysosomal storage disorders (LSDs). Therefore, the Latern Project will arrange screening as well as confirmatory DNA testing and phlebotomy services for the patients suspected to be suffering from Gaucher disease, Fabry disease, Pompe disease, mucopolysaccharidosis type I (MPS I) or acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease types A and B.

Key features of the study:

  • This report provides in-depth analysis of the global mucopolysaccharidosis (MPS) treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global mucopolysaccharidosis (MPS) treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global mucopolysaccharidosis (MPS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global mucopolysaccharidosis (MPS) treatment market

Detailed Segmentation:

  • Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment:
    • Enzyme Replacement Therapy
    • Stem Cell Therapy
  • Global Mucopolysaccharidosis (MPS) Treatment Market, By MPS Type:
    • MPS-I
    • MPS-II
    • MPS-IV
    • MPS-VI
    • MPS-VII
    • Others (MPS-III and MPS-IX)
  • Global Mucopolysaccharidosis (MPS) Treatment Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Others
  • Global Mucopolysaccharidosis (MPS) Treatment Market, By Region:
    • North America
      • By Treatment:
      • Enzyme Replacement Therapy
      • Stem Cell Therapy
      • By MPS Type
      • MPS-I
      • MPS-II
      • MPS-IV
      • MPS-VI
      • MPS-VII
      • Others (MPS-III and MPS-IX)
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Others
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Treatment:
      • Enzyme Replacement Therapy
      • Stem Cell Therapy
      • By MPS Type
      • MPS-I
      • MPS-II
      • MPS-IV
      • MPS-VI
      • MPS-VII
      • Others (MPS-III and MPS-IX)
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Others
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Treatment:
      • Enzyme Replacement Therapy
      • Stem Cell Therapy
      • By MPS Type
      • MPS-I
      • MPS-II
      • MPS-IV
      • MPS-VI
      • MPS-VII
      • Others (MPS-III and MPS-IX)
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Others
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Treatment:
      • Enzyme Replacement Therapy
      • Stem Cell Therapy
      • By MPS Type
      • MPS-I
      • MPS-II
      • MPS-IV
      • MPS-VI
      • MPS-VII
      • Others (MPS-III and MPS-IX)
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Others
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Treatment:
      • Enzyme Replacement Therapy
      • Stem Cell Therapy
      • By MPS Type
      • MPS-I
      • MPS-II
      • MPS-IV
      • MPS-VI
      • MPS-VII
      • Others (MPS-III and MPS-IX)
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Others
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Treatment:
      • Enzyme Replacement Therapy
      • Stem Cell Therapy
      • By MPS Type
      • MPS-I
      • MPS-II
      • MPS-IV
      • MPS-VI
      • MPS-VII
      • Others (MPS-III and MPS-IX)
      • By End User:
      • Hospitals
      • Specialty Clinics
      • Others
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Takeda Pharmaceutical Company Limited*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • BioMarin Pharmaceuticals, Inc.
    • Ultragenyx Pharmaceutical Inc.
    • Sarepta Therapeutics
    • Abeona Therapeutics Inc.
    • Eloxx Pharmaceuticals
    • Esteve
    • Immusoft Corporation
    • Inventiva
    • GC Pharma
    • JCR Pharmaceuticals Co Ltd.
    • RegenxBio Inc.
    • Sangamo Therapeutics, Inc.
    • Bioasis Technologies Inc.
    • Paradigm Biopharmaceuticals Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Treatment
    • Market Snippet, By MPS Type
    • Market Snippet, By End User
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Key Developments
  • PEST Analysis

4. Global Mucopolysaccharidosis (MPS) Treatment Market - Impact of Coronavirus (Covid-19) Pandemic

  • During-COVID 19 Market Analysis
  • Post-COVID 19 Market Analysis
  • Key Developments

1. Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Enzyme Replacement Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Stem Cell Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

2. Global Mucopolysaccharidosis (MPS) Treatment Market, By MPS Type, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • MPS-I
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • MPS-II
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • MPS-IV
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • MPS-VI
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • MPS-VII
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others (MPS-III and MPS-IX)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

3. Global Mucopolysaccharidosis (MPS) Treatment Market, By End User, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

4. Global Mucopolysaccharidosis (MPS) Treatment Market, By Region, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2027
  • North America
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By MPS Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By MPS Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By MPS Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By MPS Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By MPS Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Treatment, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By MPS Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

5. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • BioMarin Pharmaceuticals, Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Ultragenyx Pharmaceutical Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sarepta Therapeutics
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Abeona Therapeutics Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Eloxx Pharmaceuticals
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Esteve
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Immusoft Corporation
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Inventiva
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • GC Pharma
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • JCR Pharmaceuticals Co Ltd.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • RegenxBio Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sangamo Therapeutics, Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bioasis Technologies Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Paradigm Biopharmaceuticals Ltd.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

6. Section

  • References
  • Research Methodology
  • About us and Sales Contact